These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 17640854)

  • 1. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.
    Thompson MA; Witzig TE; Kumar S; Timm MM; Haug J; Fonseca R; Greipp PR; Lust JA; Rajkumar SV
    Br J Haematol; 2003 Oct; 123(2):305-8. PubMed ID: 14531913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
    Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
    Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant.
    Sucak GT; Aki SZ; Yüzbaşioğlu B; Akyürek N; Yağci M; Bağriaçik U; Haznedar R
    Leuk Lymphoma; 2011 Jul; 52(7):1281-9. PubMed ID: 21599578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angiogenesis in patients with hematologic malignancies].
    Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
    Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS; Kumar L; Dinda AK; Dawar R
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.
    Kim C; Lee HS; Min CK; Lee JJ; Kim K; Yoon DH; Eom HS; Lee H; Lee WS; Shin HJ; Lee JH; Park Y; Jo JC; Do YR; Mun YC
    Korean J Intern Med; 2015 Sep; 30(5):675-83. PubMed ID: 26354062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis in multiple myeloma.
    Rajkumar SV; Kyle RA
    Semin Oncol; 2001 Dec; 28(6):560-4. PubMed ID: 11740809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.
    Dmoszyńska A; Bojarska-Junak A; Domański D; Roliński J; Hus M; Soroka-Wojtaszko M
    Leuk Lymphoma; 2002 Feb; 43(2):401-6. PubMed ID: 11999576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
    Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
    Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
    Young RJ; Tin AW; Brown NJ; Jitlal M; Lee SM; Woll PJ
    Br J Cancer; 2012 Mar; 106(6):1153-9. PubMed ID: 22353811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
    McMeekin DS; Sill MW; Benbrook D; Darcy KM; Stearns-Kurosawa DJ; Eaton L; Yamada SD;
    Gynecol Oncol; 2007 May; 105(2):508-16. PubMed ID: 17306350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of thalidomide in refractory multiple myeloma.
    Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
    N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of thalidomide and its analogues: implications for anticancer therapy.
    Teo SK
    AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance.
    Marković O; Marisavljević D; Cemerikić V; Vidović A; Perunicić M; Todorović M; Elezović I; Colović M
    Med Oncol; 2008; 25(4):451-7. PubMed ID: 18449811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
    Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
    Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma.
    Prince HM; Schenkel B; Mileshkin L
    Leuk Lymphoma; 2007 Jan; 48(1):46-55. PubMed ID: 17325847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.